Back

Prevalence and prognostic utility of cirrhotic cardiomyopathy among patients with liver cirrhosis

30 August 2025 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Autoimmunity in focus Autoimmune/Chronic Inflammatory Disorders and Heart Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Ioannis Dimitroglou

Hippokration General Hospital, Athens (Greece)

4 More presentations in this session

Presentation thumbnail
Assessment of the accuracy of the HeartInsight system in predicting worsening heart failure in Japanese patients: A comparison between females and males
Doctor Y. Takanashi (Chiba, JP)
Abstract Slides Video
Presentation thumbnail
Clinical utility of the FIB-4 index for predicting cardiovascular outcomes in patients with metabolic dysfunction-associated steatotic liver disease: a 10-year retrospective cohort study
Assistant Professor P. Teerawongsakul (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
The risk of incident atrial fibrillation in patients with inflammatory arthritis: a hierarchical clustering approach from the Hong Kong Hospital Authority Data Collaboration Laboratory (HADCL)
Doctor S. Lam (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
The effect of 4-month treatment with glycocalyx dietary supplement on endothelial glycocalyx integrity and vascular function in patients with psoriasis
Doctor D. Vlachomitros (Marousi, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Autoimmunity in focus

The Event

Event poster

ESC Congress 2025

30 August 2025 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Profiles of patients with cardiovascular risk factors and the severity of hepatic steatosis and fibrosis assessed by pulsed ultrasound
thumbnail
Congress Presentation
Prognostic value of right ventricular dysfunction and right ventricular arterial coupling in patients with liver cirrhosis
thumbnail
Congress Presentation
Fatty liver disease as risk factors for the clinical expression of hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources